Leiner Suspends U.S. OTC Operations, Expects Perrigo To Meet Demand
This article was originally published in The Tan Sheet
Executive Summary
Leiner Health Products expects to lose business to competing private-labeler Perrigo following the voluntary suspension of its U.S. OTC operations
You may also be interested in...
Leiner Proposes $10 Million Restitution To Enhance Its Value
Leiner Health Products describes a proposed agreement with federal investigators as a key to restarting its U.S. OTC business, but the firm's debt load makes it more likely the business will be sold
Leiner Proposes $10 Million Restitution To Enhance Its Value
Leiner Health Products describes a proposed agreement with federal investigators as a key to restarting its U.S. OTC business, but the firm's debt load makes it more likely the business will be sold
Leiner Proposes $10 Million Restitution To Enhance Its Value
Leiner Health Products describes a proposed agreement with federal investigators as a key to restarting its U.S. OTC business, but the firm's debt load makes it more likely the business will be sold